Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung ...

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study describe what characterizes the group of patients with nonmetastatic castration-resistant prostate ...

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with nonmetastatic castration-resistant prostate ...

In this MEDtalk, Eric J. Small talks about to which extent patients with non-metastatic castration-resistant prostate cancer achieve metastasis-free survival and whether it is possible to delay the time until chemotherapy, as well as the impact of treatment on ...

Eric J. Small, MD and principal investigator of the SPARTAN study explains the background and study design of the SPARTAN study, where the efficiency and safety of apalutamide for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) was ...

The COVID-19 pandemic has changed the format of this year’s ASCO Annual Meeting. The conference ran from 29 – 31 May under the theme ‘Unite and Conquer: Accelerating Progress Together.’ This year’s scientific program featured more than 250 oral presentations and 2,500 poster presentations in 24 disease-based and specialty tracks. In the opening session on ...

Results from a post hoc analysis of the SPARTAN Phase III study of apalutamide showed that regardless of genetic subclass, the treatment significantly improved the metastasis-free survival of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). For more than 50% of patients treated with apalutamide, a ≥ 90% reduction in PSA was observed. The results was ...

Three new therapeutic agents for the treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC), apalutamid, darolutamid and enzalutamid, have recently been FDA approved. Not alone are the therapies new, they also open up to the treatment of a whole new group of patients, for whom there was no treatment possibility earlier. It raises several questions. On ...

Dr. David Fajgenbaum was close to dying of Castleman’s disease, but ended up pursuing a cure for this rare disease. In this ASCO podcast episode, Dr. David Fajgenbaum, American immunologist and author, tells about his involvement in finding a cure for the rare Castleman’s disease. He discusses his methodical experiences and relates them to the ...

Martin Reck, MD and Ph.D at the German Center of Lung Research, presented at this year’s ASCO20 Virtual Scientific program the first results from the CheckMate 9LA trial – a randomized trial investigating the combination of a limited cause of chemotherapy together with nivolumab and ipilimumab as first line treatment for patients with advanced non ...

#Senaste tidskrift

BestPractice Nordic

Nr. 1 • mars 2020
1. Årgang
  • Hjärt-kärlsjukdom
  • Blodtrycksmätning
  • Inkretinbehandling